Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

[1]  V. Ambrosini,et al.  Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  M. Papotti,et al.  Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors , 2002, Virchows Archiv.

[3]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[4]  J. Carrasquillo,et al.  The Effects of Carbidopa on Uptake of 6-18F-Fluoro-l-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma , 2007, Journal of Nuclear Medicine.

[5]  K. Gulenchyn,et al.  6-l-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications* , 2008, Journal of Nuclear Medicine.

[6]  M E Phelps,et al.  Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. , 1990, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[7]  M. Bergström,et al.  Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  J. Foidart,et al.  Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67 , 2002, Nuclear medicine communications.

[9]  B. Wiedenmann,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma , 2007, Neuroendocrinology.

[10]  J. Talbot,et al.  Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Marion de Jong,et al.  Radiolabelling DOTA-peptides with 68Ga , 2005, European Journal of Nuclear Medicine and Molecular Imaging.